News

Novo Nordisk to offer Ozempic at $499 per month to eligible US customers

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...
InvestorsHub on MSN1h

Novo Nordisk Climbs Following FDA Approval of Wegovy for Liver Disease

Shares of Novo Nordisk (NYSE:NVO) rose 2.4% in pre-market trading Monday in New York after the FDA approved Wegovy for ...

Novo Advances After US Clears Wegovy for Liver Disease

Novo Nordisk A/S shares advanced after the drugmaker’s blockbuster weight-loss drug Wegovy received US approval to treat a ...

Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here’s Why It’s Down

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict ...